How did OCUL's revenue and expenses trend in Q4 2024?
4/14/2025 10:29am
Aime
Ocular Therapeutix (OCUL) experienced a significant decline in net income in Q4 2024, with a net loss of $48.39 million, despite a total revenue of $17.08 million. The R&D expenses were notably high at $40.99 million for the quarter1.
OCUL R&D Expenses, Total Revenue...
Source:
1.
OCUL Revenue (Q4 2024), R&D Expenses (Q4 2024), SG&A Expenses (Q4 2024), Net Income (Q4 2024)
more
less
Explore
Screener
What are the best stocks to buy now?
Analysis
Aple Rating chart
Learn
Advanced technical indicators and how they are calculated and utilized